Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANGELA YEN MOORE

Allopathic & Osteopathic Physicians Dermatology Dermatopathology

NPI
1235142266
CMS profile
328697
Location
ARLINGTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$115,344.28

308 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 6 of 7; records 251–300 of 308 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANGELA YEN MOORE

NPI 1235142266 · CMS profile ID 328697

Allopathic & Osteopathic Physicians / Dermatology / Dermatopathology

ARLINGTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 6 of 7; records 251–300 of 308 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1235142266?year=2019&recipient=provider&page=6#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANGELA YEN MOORE, NPI 1235142266, CMS profile ID 328697. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 7; records 251–300 of 308 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1235142266?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ANGELA YEN MOORE, NPI 1235142266, CMS profile ID 328697. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 7; records 251–300 of 308 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1235142266?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ANGELA YEN MOORE, NPI 1235142266, CMS profile ID 328697, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 7; records 251–300 of 308 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1235142266?year=2019&recipient=provider&page=6#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

308 matching records · $115,344.28 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 308 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 251–300 of 308.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie, Inc. $119.7003/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647827283 CMS
Almirall LLC $58.4303/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676665521 CMS
Celgene Corporation $97.8503/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672749223 CMS
Lilly USA, LLC $24.5003/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657691285 CMS
PFIZER INC. $46.2703/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672124773 CMS
Biofrontera Inc. $39.5503/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 667996929 CMS
AbbVie, Inc. $118.2002/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647827319 CMS
E.R. Squibb & Sons, L.L.C. $124.7402/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651439963 CMS
E.R. Squibb & Sons, L.L.C. $15.1602/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651439965 CMS
Mayne Pharma Inc. $13.2002/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705510363 CMS
Mayne Pharma Inc. $1.7102/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705510365 CMS
Mayne Pharma Inc. $2.5302/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705510369 CMS
Mayne Pharma Inc. $13.1702/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705510371 CMS
AbbVie, Inc. $23.2102/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647827285 CMS
Almirall LLC $18.4002/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676665505 CMS
Almirall LLC $24.9402/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676665489 CMS
Almirall LLC $52.4502/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676665494 CMS
Almirall LLC $149.2902/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676665481 CMS
Almirall LLC $27.2602/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676665485 CMS
Janssen Biotech, Inc. $22.0702/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658603063 CMS
Aclaris Therapeutics, Inc. $500.0002/19/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700983529 CMS
Biofrontera Inc. $83.1902/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 667996587 CMS
Mayne Pharma Inc. $12.5502/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705510359 CMS
Mayne Pharma Inc. $16.1402/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705510353 CMS
Mayne Pharma Inc. $2.9602/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705510357 CMS
Promius Pharma LLC $22.7802/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701093027 CMS
Almirall LLC $103.1402/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676665477 CMS
Almirall LLC $16.8202/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676665473 CMS
Almirall LLC $112.3802/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676665461 CMS
Almirall LLC $24.3602/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676665469 CMS
Janssen Biotech, Inc. $1.5402/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658603014 CMS
Mayne Pharma Inc. $18.9702/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705510351 CMS
Almirall LLC $132.3202/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676665445 CMS
Almirall LLC $22.6202/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676665447 CMS
Almirall LLC $48.8002/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676665437 CMS
Almirall LLC $20.8802/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676665441 CMS
LEO Pharma Inc. $18.9001/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687267715 CMS
Mayne Pharma Inc. $6.1301/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705510347 CMS
Novartis Pharmaceuticals Corporation $92.1401/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659769833 CMS
Mayne Pharma Inc. $20.0001/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705510343 CMS
Mayne Pharma Inc. $1.5501/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705510345 CMS
AbbVie, Inc. $22.6401/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647827281 CMS
Almirall LLC $119.4001/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676665429 CMS
Mayne Pharma Inc. $2.7701/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705510337 CMS
Mayne Pharma Inc. $9.0801/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705510339 CMS
Almirall LLC $25.2301/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676665407 CMS
Almirall LLC $5,000.0001/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676665411 CMS
AbbVie, Inc. $2,875.0001/16/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647827275 CMS
Mayne Pharma Inc. $13.6701/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705510335 CMS
AbbVie, Inc. $40.4401/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647827277 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $115,344.28 308
PY2020 $52,594.21 159
PY2021 $46,475.30 122
PY2022 $84,732.10 146
PY2023 $56,021.90 177
PY2024 $50,554.66 151
PY2025 $17,542.31 149

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,778,173.66 254
PY2024 Principal investigator $2,059,458.30 319
PY2023 Principal investigator $1,094,340.18 232
PY2022 Principal investigator $1,164,547.07 178
PY2021 Recipient $27,537.00 2
PY2021 Principal investigator $1,089,255.21 188
PY2020 Principal investigator $700,899.48 135
PY2019 Recipient $11,250.00 1
PY2019 Principal investigator $1,162,550.93 139

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

254 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,529.40 12/31/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata No dispute reported 06/30/2026 1202534603
Principal investigator 1 Janssen Research & Development, LLC $2,650.00 12/29/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1175344862
Principal investigator 1 Janssen Research & Development, LLC $5,094.00 12/25/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175344822
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 12/25/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175344891
Principal investigator 1 PFIZER INC. $5,893.13 12/25/2025 Non-covered Recipient Entity
Arlington Research Center
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228743685
Principal investigator 1 Janssen Research & Development, LLC $3,762.00 12/22/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surface Area No dispute reported 06/30/2026 1175344936
Principal investigator 1 SANOFI US SERVICES INC. $12,357.20 12/22/2025 Non-covered Recipient Entity
Arlington Research Center Inc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226103653
Principal investigator 1 Janssen Research & Development, LLC $5,093.00 12/19/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175344746
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,366.25 12/18/2025 Non-covered Recipient Entity
Arlington Research Center INC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246430826
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $127.40 12/17/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223289872
Principal investigator 1 Janssen Research & Development, LLC $5,286.00 12/15/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175344664
Principal investigator 1 Janssen Research & Development, LLC $8,000.50 12/15/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175344755
Principal investigator 1 Janssen Research & Development, LLC $5,778.00 12/15/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175344799
Principal investigator 1 Janssen Research & Development, LLC $7,000.00 12/15/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175344817
Principal investigator 1 SANOFI US SERVICES INC. $31,208.00 12/15/2025 Non-covered Recipient Entity
Arlington Research Center Inc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226103659
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $51,443.60 12/10/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289494
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,755.00 12/10/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289506
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,800.00 12/10/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289508
Principal investigator 1 ABBVIE INC. $6,568.75 12/04/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202529126
Principal investigator 1 ABBVIE INC. $1,832.25 12/04/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1202529128
Principal investigator 1 ABBVIE INC. $1,998.75 12/04/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202529130
Principal investigator 1 ABBVIE INC. $5,553.04 12/04/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202529132
Principal investigator 1 ABBVIE INC. $4,213.75 12/04/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202529134
Principal investigator 1 Incyte Corporation $9.54 12/01/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503479
Principal investigator 1 Incyte Corporation $47.40 12/01/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503490
Principal investigator 1 Incyte Corporation $14.22 12/01/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503494
Principal investigator 1 Incyte Corporation $24.66 12/01/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503498
Principal investigator 1 Incyte Corporation $24.66 12/01/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503503
Principal investigator 1 Incyte Corporation $24.66 12/01/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503507
Principal investigator 1 Incyte Corporation $24.66 12/01/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503509
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503514
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503518
Principal investigator 1 Janssen Research & Development, LLC $7,916.00 12/01/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175344764
Principal investigator 1 Janssen Research & Development, LLC $10,123.00 12/01/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175344772
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,244.90 12/01/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289071
Principal investigator 1 Janssen Research & Development, LLC $5,000.00 11/26/2025 Non-covered Recipient Entity
Arlington Rsrch Ctr
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175274936
Principal investigator 1 Janssen Research & Development, LLC $1,071.00 11/26/2025 Non-covered Recipient Entity
Arlington Rsrch Ctr
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175275161
Principal investigator 1 Eli Lilly and Company $25,884.00 11/24/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187876467
Principal investigator 1 SANOFI US SERVICES INC. $2,897.50 11/24/2025 Non-covered Recipient Entity
Arlington Research Center Inc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226103647
Principal investigator 1 PFIZER INC. $1,843.75 11/18/2025 Non-covered Recipient Entity
Arlington Research Center
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228727215
Principal investigator 1 Janssen Research & Development, LLC $9,229.00 11/17/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Study to Evaluate the Efficacy Safety and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants No dispute reported 06/30/2026 1175344908
Principal investigator 1 SANOFI US SERVICES INC. $33,251.00 11/17/2025 Non-covered Recipient Entity
Arlington Research Center Inc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226103641
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,122.50 11/13/2025 Non-covered Recipient Entity
Arlington Research Center INC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246430824
Principal investigator 1 ABBVIE INC. $2,400.00 11/06/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202523359
Principal investigator 1 ABBVIE INC. $2,353.75 11/05/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202522247
Principal investigator 1 ABBVIE INC. $7,944.01 11/05/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202522327
Principal investigator 1 ABBVIE INC. $4,193.26 11/05/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202522329
Principal investigator 1 ABBVIE INC. $3,289.00 11/04/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202520575
Principal investigator 1 ABBVIE INC. $27,688.75 11/04/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202520577
Principal investigator 1 Hoffmann-La Roche Limited $1,651.00 11/03/2025 Non-covered Recipient Entity
Arlington Research Center
VELARITE No dispute reported 06/30/2026 1211573619
Principal investigator 1 Incyte Corporation $137.40 11/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503482
Principal investigator 1 Incyte Corporation $74.04 11/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503486
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $31,682.30 11/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287867
Principal investigator 1 Janssen Research & Development, LLC $4,720.00 10/31/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175344930
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $61.29 10/30/2025 Non-covered Recipient Entity
Arlington Center For Dermatology
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235998920
Principal investigator 1 Novartis Pharmaceuticals Corporation $59,276.68 10/28/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1190307239
Principal investigator 1 Janssen Research & Development, LLC $1,762.00 10/27/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175344608
Principal investigator 1 Janssen Research & Development, LLC $7,894.00 10/24/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175344558
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,670.63 10/23/2025 Non-covered Recipient Entity
Arlington Research Center INC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246430820
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $10,402.51 10/23/2025 Non-covered Recipient Entity
Arlington Research Center INC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246430822
Principal investigator 1 SANOFI US SERVICES INC. $2,835.80 10/14/2025 Non-covered Recipient Entity
Arlington Research Center Inc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226103635
Principal investigator 1 PFIZER INC. $4,386.88 10/11/2025 Non-covered Recipient Entity
Arlington Research Center
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228741182
Principal investigator 1 ABBVIE INC. $4,002.88 10/09/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202515787
Principal investigator 1 ABBVIE INC. $41.25 10/09/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202515789
Principal investigator 1 ABBVIE INC. $2,096.63 10/09/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202515791
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,459.38 10/09/2025 Non-covered Recipient Entity
Arlington Research Center INC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246430818
Principal investigator 1 Novartis Pharmaceuticals Corporation $31,360.87 10/08/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190307241
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,421.80 10/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286319
Principal investigator 1 Hoffmann-La Roche Limited $2,130.00 10/02/2025 Non-covered Recipient Entity
Arlington Research Center
VELARITE No dispute reported 06/30/2026 1211573610
Principal investigator 1 Hoffmann-La Roche Limited $2,496.00 10/02/2025 Non-covered Recipient Entity
Arlington Research Center
VELARITE No dispute reported 06/30/2026 1211573614
Principal investigator 1 Janssen Research & Development, LLC $4,399.00 09/29/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175344688
Principal investigator 1 Janssen Research & Development, LLC $6,317.00 09/29/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1175344700
Principal investigator 1 Janssen Research & Development, LLC $2,243.00 09/29/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175344830
Principal investigator 1 SANOFI US SERVICES INC. $170,757.00 09/29/2025 Non-covered Recipient Entity
Arlington Research Center Inc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226103619
Principal investigator 1 Janssen Research & Development, LLC $5,420.00 09/22/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175344922
Principal investigator 1 SANOFI US SERVICES INC. $15,000.00 09/22/2025 Non-covered Recipient Entity
Arlington Research Center Inc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226103615
Principal investigator 1 Incyte Corporation $1,924.20 09/10/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503475
Principal investigator 1 PFIZER INC. $7,000.00 09/10/2025 Non-covered Recipient Entity
Arlington Research Center
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228723054
Principal investigator 1 Janssen Research & Development, LLC $4,458.00 09/08/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175344599
Principal investigator 1 Janssen Research & Development, LLC $2,243.00 09/08/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175344789
Principal investigator 1 SANOFI US SERVICES INC. $2,102.50 09/08/2025 Non-covered Recipient Entity
Arlington Research Center Inc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226103609
Principal investigator 1 ABBVIE INC. $1,931.25 09/04/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202509236
Principal investigator 1 ABBVIE INC. $7,602.50 09/04/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202509250
Principal investigator 1 ABBVIE INC. $11,823.39 09/04/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202509252
Principal investigator 1 Hoffmann-La Roche Limited $1,813.00 09/04/2025 Non-covered Recipient Entity
Arlington Research Center
VELARITE No dispute reported 06/30/2026 1211573593
Principal investigator 1 Hoffmann-La Roche Limited $2,018.00 09/04/2025 Non-covered Recipient Entity
Arlington Research Center
VELARITE No dispute reported 06/30/2026 1211573598
Principal investigator 1 Janssen Research & Development, LLC $6,251.00 09/04/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175344679
Principal investigator 1 Janssen Research & Development, LLC $8,130.00 09/01/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175344715
Principal investigator 1 Janssen Research & Development, LLC $864.00 08/29/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1175344915
Principal investigator 1 Janssen Research & Development, LLC $10,165.00 08/29/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1175344958
Principal investigator 1 ABBVIE INC. $1,750.00 08/25/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) No dispute reported 06/30/2026 1202505669
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,548.80 08/22/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223284523
Principal investigator 1 Biofrontera Inc. $425.00 08/15/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A SINGLE CENTER, OPEN-LABEL, PROSPECTIVE STUDY ON THE EFFICACY AND SAFETY OF PHOTODYNAMIC THERAPY WITH AMINOLEVULINIC ACID HYDROCHLORIDE 10% GEL (ALA GEL) FOR ADULT SUBJECTS WITH ONYCHOMYCOSIS No dispute reported 06/30/2026 1208907583
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,400.01 08/13/2025 Non-covered Recipient Entity
Arlington Research Center INC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246430816
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,334.83 08/13/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223284209
Principal investigator 1 SANOFI US SERVICES INC. $2,980.50 08/11/2025 Non-covered Recipient Entity
Arlington Research Center Inc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226103603
Principal investigator 1 Janssen Research & Development, LLC $7,597.00 08/08/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1175344949
Principal investigator 1 ABBVIE INC. $16,193.75 08/06/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202502470
Principal investigator 1 ABBVIE INC. $11,885.13 08/06/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202502472
Principal investigator 1 ABBVIE INC. $3,862.50 08/06/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202502532
Principal investigator 1 Incyte Corporation $16.44 08/06/2025 Non-covered Recipient Entity
PROGRESSIVE CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577751
Principal investigator 1 Incyte Corporation $9.72 08/06/2025 Non-covered Recipient Entity
PROGRESSIVE CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577760
Principal investigator 1 Incyte Corporation $32.36 08/06/2025 Non-covered Recipient Entity
PROGRESSIVE CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577766
Principal investigator 1 Incyte Corporation $49.36 08/06/2025 Non-covered Recipient Entity
PROGRESSIVE CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577773
Principal investigator 1 Incyte Corporation $0.62 08/06/2025 Non-covered Recipient Entity
PROGRESSIVE CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577777
Principal investigator 1 Incyte Corporation $16.44 08/06/2025 Non-covered Recipient Entity
PROGRESSIVE CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577783
Principal investigator 1 Incyte Corporation $16.44 08/06/2025 Non-covered Recipient Entity
PROGRESSIVE CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577789
Principal investigator 1 Incyte Corporation $16.44 08/06/2025 Non-covered Recipient Entity
PROGRESSIVE CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240577795
Principal investigator 1 ABBVIE INC. $294.75 08/05/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1202501342
Principal investigator 1 ABBVIE INC. $1,542.00 08/05/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202501344
Principal investigator 1 Hoffmann-La Roche Limited $1,863.00 08/01/2025 Non-covered Recipient Entity
Arlington Research Center
VELARITE No dispute reported 06/30/2026 1211573606
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,639.00 08/01/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283747
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,925.10 08/01/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283749
Principal investigator 1 ABBVIE INC. $7,700.00 07/29/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202500364
Principal investigator 1 ABBVIE INC. $2,400.00 07/29/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202500372
Principal investigator 1 Janssen Research & Development, LLC $3,704.00 07/28/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175344654
Principal investigator 1 Janssen Research & Development, LLC $12,503.00 07/28/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175344848
Principal investigator 1 SANOFI US SERVICES INC. $4,861.90 07/14/2025 Non-covered Recipient Entity
Arlington Research Center Inc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226103589
Principal investigator 1 Janssen Research & Development, LLC $5,000.00 07/10/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1175344810
Principal investigator 1 Janssen Research & Development, LLC $1,881.00 07/10/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175344869
Principal investigator 1 Incyte Corporation $1,346.40 07/09/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503471
Principal investigator 1 PFIZER INC. $13,440.00 07/09/2025 Non-covered Recipient Entity
Arlington Research Center
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228720231
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,663.90 07/09/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223282426
Principal investigator 1 ABBVIE INC. $11,015.75 07/08/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202497320
Principal investigator 1 ABBVIE INC. $6,971.63 07/08/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202497342
Principal investigator 1 ABBVIE INC. $4,303.75 07/02/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202495753
Principal investigator 1 ABBVIE INC. $11,552.50 07/02/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202495755
Principal investigator 1 Arcutis Biotherapeutics, Inc. $3,510.07 07/02/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Pharmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata No dispute reported 06/30/2026 1248163696
Principal investigator 1 Hoffmann-La Roche Limited $2,500.00 07/02/2025 Non-covered Recipient Entity
Arlington Research Center
VELARITE No dispute reported 06/30/2026 1211573602
Principal investigator 1 SANOFI US SERVICES INC. $4,819.00 07/02/2025 Non-covered Recipient Entity
Arlington Research Center Inc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226103595
Principal investigator 1 Janssen Research & Development, LLC $6,596.00 06/30/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175344634
Principal investigator 1 Janssen Research & Development, LLC $20,567.00 06/30/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1175344642
Principal investigator 1 Janssen Research & Development, LLC $10,710.00 06/26/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175344885
Principal investigator 1 Janssen Research & Development, LLC $9,633.00 06/23/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175344583
Principal investigator 1 Genentech, Inc. $1,968.00 06/18/2025 Non-covered Recipient Entity
Arlington Research Center
VELARITE No dispute reported 06/30/2026 1211573569
Principal investigator 1 Genentech, Inc. $2,130.00 06/18/2025 Non-covered Recipient Entity
Arlington Research Center
VELARITE No dispute reported 06/30/2026 1211573573
Principal investigator 1 Genentech, Inc. $1,813.00 06/18/2025 Non-covered Recipient Entity
Arlington Research Center
VELARITE No dispute reported 06/30/2026 1211573581
Principal investigator 1 Genentech, Inc. $1,623.00 06/18/2025 Non-covered Recipient Entity
Arlington Research Center
VELARITE No dispute reported 06/30/2026 1211573585
Principal investigator 1 Genentech, Inc. $2,496.00 06/18/2025 Non-covered Recipient Entity
Arlington Research Center
VELARITE No dispute reported 06/30/2026 1211573589
Principal investigator 1 Janssen Research & Development, LLC $3,805.00 06/13/2025 Non-covered Recipient Entity
Arlington Rsrch Ctr
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175275002
Principal investigator 1 Incyte Corporation $1,346.40 06/11/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503450
Principal investigator 1 Janssen Research & Development, LLC $1,881.00 06/09/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175344780
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,181.95 06/06/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223280928
Principal investigator 1 ABBVIE INC. $10,991.26 06/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202489419
Principal investigator 1 ABBVIE INC. $6,342.00 06/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202489653
Principal investigator 1 ABBVIE INC. $8,208.75 06/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202489655
Principal investigator 1 ABBVIE INC. $1,347.50 06/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202489657
Principal investigator 1 ABBVIE INC. $312.25 06/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202489659
Principal investigator 1 ABBVIE INC. $1,789.75 06/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1202489661
Principal investigator 1 Incyte Corporation $12.36 06/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503400
Principal investigator 1 Incyte Corporation $49.32 06/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503407
Principal investigator 1 Incyte Corporation $135.40 06/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503414
Principal investigator 1 Incyte Corporation $62.27 06/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503419
Principal investigator 1 Incyte Corporation $54.76 06/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503423
Principal investigator 1 Incyte Corporation $49.32 06/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503427
Principal investigator 1 Incyte Corporation $14.84 06/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503433
Principal investigator 1 Incyte Corporation $49.36 06/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503438
Principal investigator 1 Incyte Corporation $64.72 06/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503444
Principal investigator 1 Incyte Corporation $68.70 06/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503454
Principal investigator 1 Incyte Corporation $59.13 06/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503459
Principal investigator 1 Incyte Corporation $49.32 06/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503463
Principal investigator 1 Incyte Corporation $49.32 06/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503467
Principal investigator 1 Janssen Research & Development, LLC $11,950.00 05/26/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175344856
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,978.31 05/23/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223280302
Principal investigator 1 Janssen Research & Development, LLC $7,508.00 05/22/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175344737
Principal investigator 1 Janssen Research & Development, LLC $7,000.00 05/19/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175344647
Principal investigator 1 SANOFI US SERVICES INC. $9,919.20 05/19/2025 Non-covered Recipient Entity
Arlington Research Center Inc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226103582
Principal investigator 1 Genentech, Inc. $3,000.00 05/14/2025 Non-covered Recipient Entity
Arlington Research Center
VELARITE No dispute reported 06/30/2026 1211573577
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 05/14/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223279758
Principal investigator 1 Janssen Research & Development, LLC $2,664.00 05/09/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175344901
Principal investigator 1 ABBVIE INC. $11,435.25 05/07/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202482475
Principal investigator 1 ABBVIE INC. $6,707.63 05/07/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202482477
Principal investigator 1 ABBVIE INC. $20,127.50 05/07/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202483213
Principal investigator 1 ABBVIE INC. $5,576.25 05/06/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202481229
Principal investigator 1 ABBVIE INC. $1,263.50 05/06/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202481717
Principal investigator 1 SANOFI US SERVICES INC. $32,387.50 05/05/2025 Non-covered Recipient Entity
Arlington Research Center Inc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226103578
Principal investigator 1 Janssen Research & Development, LLC $2,995.00 04/28/2025 Non-covered Recipient Entity
Arlington Rsrch Ctr
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175275013
Principal investigator 1 Janssen Research & Development, LLC $3,934.00 04/28/2025 Non-covered Recipient Entity
Arlington Rsrch Ctr
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175275081
Principal investigator 1 Janssen Research & Development, LLC $6,168.00 04/28/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175344730
Principal investigator 1 Incyte Corporation $1,700.00 04/25/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1240503395
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,925.20 04/11/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278024
Principal investigator 1 Incyte Corporation $1,346.40 04/09/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503411
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,046.06 04/09/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223277734
Principal investigator 1 ABBVIE INC. $4,118.25 04/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202470673
Principal investigator 1 ABBVIE INC. $14,665.00 04/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202470677
Principal investigator 1 ABBVIE INC. $2,116.25 04/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202470682
Principal investigator 1 ABBVIE INC. $4,921.25 04/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202470685
Principal investigator 1 Janssen Research & Development, LLC $2,664.00 03/31/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175344577
Principal investigator 1 Incyte Corporation $133.06 03/27/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1240503391
Principal investigator 1 Janssen Research & Development, LLC $10,190.00 03/27/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175344592
Principal investigator 1 Janssen Research & Development, LLC $4,976.00 03/24/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175344723
Principal investigator 1 Janssen Research & Development, LLC $7,610.00 03/21/2025 Non-covered Recipient Entity
Arlington Rsrch Ctr
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175274956
Principal investigator 1 UCB SA $26,770.00 03/21/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB COMPARED TO USTEKINUMAB IN CHILDREN AND ADOLESCENTS FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH MODERATE TO SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 1246656306
Principal investigator 1 SANOFI US SERVICES INC. $21,379.80 03/17/2025 Non-covered Recipient Entity
Arlington Research Center Inc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226103567
Principal investigator 1 Incyte Corporation $1,346.40 03/12/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503359
Principal investigator 1 ABBVIE INC. $7,320.00 03/07/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202460415
Principal investigator 1 ABBVIE INC. $9,806.75 03/07/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202460563
Principal investigator 1 ABBVIE INC. $7,458.75 03/07/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202460567
Principal investigator 1 ABBVIE INC. $1,263.50 03/06/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202457686
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,972.72 03/05/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223276017
Principal investigator 1 Incyte Corporation $9.72 03/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503363
Principal investigator 1 Incyte Corporation $68.70 03/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503371
Principal investigator 1 Incyte Corporation $32.36 03/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503380
Principal investigator 1 Janssen Research & Development, LLC $21,334.00 03/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175344618
Principal investigator 1 Janssen Research & Development, LLC $7,887.00 03/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175344669
Principal investigator 1 UCB SA $2,190.60 03/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) No dispute reported 06/30/2026 1246659561
Principal investigator 1 Janssen Research & Development, LLC $2,995.00 02/27/2025 Non-covered Recipient Entity
Arlington Rsrch Ctr
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175275072
Principal investigator 1 Janssen Research & Development, LLC $2,995.00 02/27/2025 Non-covered Recipient Entity
Arlington Rsrch Ctr
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175275089
Principal investigator 1 Janssen Research & Development, LLC $4,589.00 02/27/2025 Non-covered Recipient Entity
Arlington Rsrch Ctr
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175275148
Principal investigator 1 Janssen Research & Development, LLC $2,995.00 02/27/2025 Non-covered Recipient Entity
Arlington Rsrch Ctr
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175275173
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $18,099.90 02/26/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223275629
Principal investigator 1 SANOFI US SERVICES INC. $53,769.30 02/18/2025 Non-covered Recipient Entity
Arlington Research Center Inc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226103559
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 02/07/2025 Non-covered Recipient Entity
Arlington Rsrch Ctr
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175275110
Principal investigator 1 Janssen Research & Development, LLC $3,744.00 02/07/2025 Non-covered Recipient Entity
Arlington Rsrch Ctr
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175275133
Principal investigator 1 Janssen Research & Development, LLC $5,500.00 02/07/2025 Non-covered Recipient Entity
Arlington Rsrch Ctr
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175275140
Principal investigator 1 Janssen Research & Development, LLC $3,766.00 02/07/2025 Non-covered Recipient Entity
Arlington Rsrch Ctr
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175275189
Principal investigator 1 ABBVIE INC. $27,721.25 02/06/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202447291
Principal investigator 1 ABBVIE INC. $8,318.75 02/06/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202447341
Principal investigator 1 ABBVIE INC. $11,692.00 02/06/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202447347
Principal investigator 1 Janssen Research & Development, LLC $1,071.00 02/06/2025 Non-covered Recipient Entity
Arlington Rsrch Ctr
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175274963
Principal investigator 1 Janssen Research & Development, LLC $3,395.00 02/06/2025 Non-covered Recipient Entity
Arlington Rsrch Ctr
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175275022
Principal investigator 1 ABBVIE INC. $312.25 02/05/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202444238
Principal investigator 1 ABBVIE INC. $294.75 02/05/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
M16-045 - Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1202445333
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $22,617.11 02/05/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274843
Principal investigator 1 Janssen Research & Development, LLC $8,371.00 01/31/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175344944
Principal investigator 1 UCB SA $13,836.00 01/31/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa No dispute reported 06/30/2026 1246657089
Principal investigator 1 Janssen Research & Development, LLC $254.00 01/29/2025 Non-covered Recipient Entity
Arlington Rsrch Ctr
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175275096
Principal investigator 1 Janssen Research & Development, LLC $254.00 01/29/2025 Non-covered Recipient Entity
Arlington Rsrch Ctr
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175275104
Principal investigator 1 Janssen Research & Development, LLC $254.00 01/29/2025 Non-covered Recipient Entity
Arlington Rsrch Ctr
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175275204
Principal investigator 1 Janssen Research & Development, LLC $1,678.00 01/27/2025 Non-covered Recipient Entity
Arlington Rsrch Ctr
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175275181
Principal investigator 1 Janssen Research & Development, LLC $19,032.00 01/27/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175344838
Principal investigator 1 Janssen Research & Development, LLC $4,491.00 01/24/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175344568
Principal investigator 1 Incyte Corporation $5,670.91 01/23/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1240503388
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,800.00 01/22/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274367
Principal investigator 1 SANOFI US SERVICES INC. $48,967.00 01/21/2025 Non-covered Recipient Entity
Arlington Research Center Inc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226103573
Principal investigator 1 Janssen Research & Development, LLC $1,508.00 01/17/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175344708
Principal investigator 1 Janssen Research & Development, LLC $3,271.00 01/17/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175344876
Principal investigator 1 Janssen Research & Development, LLC $17,105.00 01/16/2025 Non-covered Recipient Entity
Arlington Rsrch Ctr
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175275048
Principal investigator 1 Janssen Research & Development, LLC $7,000.00 01/16/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175344626
Principal investigator 1 Incyte Corporation $1,472.40 01/15/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503351
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 01/08/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223273795
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $755.00 01/08/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223273797
Principal investigator 1 Biofrontera Inc. $11,174.83 01/06/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A SINGLE CENTER, OPEN-LABEL, PROSPECTIVE STUDY ON THE EFFICACY AND SAFETY OF PHOTODYNAMIC THERAPY WITH AMINOLEVULINIC ACID HYDROCHLORIDE 10% GEL (ALA GEL) FOR ADULT SUBJECTS WITH ONYCHOMYCOSIS No dispute reported 06/30/2026 1208907239
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 01/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223273535
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 01/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223273537
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,700.00 01/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223273539
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,000.00 01/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223273541
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 01/03/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223273543
Principal investigator 1 ABBVIE INC. $1,458.00 01/02/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202433925
Principal investigator 1 ABBVIE INC. $1,832.25 01/02/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER INC
M16-045 - Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1202435193
Principal investigator 1 Incyte Corporation $201.40 01/02/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503355
Principal investigator 1 Incyte Corporation $68.90 01/02/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503367
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503376
Principal investigator 1 Incyte Corporation $37.66 01/02/2025 Non-covered Recipient Entity
ARLINGTON RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503383